TCR2 Therapeutics and Adaptimmune to Form Strategic Combination

(24/7 MARKET NEWS) – TCR² Therapeutics Inc. (NASDAQ: TCRR) and Adaptimmune Therapeutics plc (NASDAQ: ADAP) announced, this morning, that the two Companies entered into a definitive agreement under which Adaptimmune will combine with TCR² in an all-stock transaction to create a cell therapy company focused on treating solid tumors.

TCR² Therapeutics is at $1.55, up $0.34 (+28.10%), on 480 thousand premarket shares.

Adaptimmune Therapeutics is at $1.76, up $0.12 (+7.32%), on 200 thousand premarket shares.

TCR² Therapeutics 52-week trading range is $0.821 to $3.88. Its setup would be favorable for a run to $2.50, but this news is likely to keep that from happening.

Adaptimmune Therapeutics 52-week trading range is $1.01 to $2.65. It tends to make parabolic moves.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to or for further information.


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist